NCT06533254 Behavioral AI to Predict and Increase Peritoneal Dialysis Uptake
| NCT ID | NCT06533254 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Scaled Insights |
| Condition | Chronic Kidney Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2025-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2024-09-01 with a primary completion date of 2025-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Scaled Insights Behavioral AI will be used to improve clinicians ability to detect and understand: The likelihood of patients with kidney failure opting for peritoneal dialysis and to select the right personalized nudge to get CKD patients to choose peritoneal dialysis Scaled Insights' can utilize the data from this study to develop individualized nudges for healthcare professionals that can be broadly deployed within a digital platform so that clinics across the English speaking world can use it as a means of supporting patients with CKD in selecting peritoneal dialysis treatment. Using Scaled Insights novel Behavioral Artificial Intelligence solution, the proposed project has two aims: 1. to identify personality attributes of patients with Chronic Kidney Disease and correlating their personality attributes with their subsequent choice of dialysis. Once correlated into personality based clusters, the AI Model will then be able will determine which personality cluster each net new patient will fall into and therefore predict their specific likelihood of opting for peritoneal dialysis or hemodialysis 2. once prediction is possible, customized nudges towards the selection of PD will be developed and tested to improve the likelihood that patients will opt for peritoneal dialysis Hypotheses: 1. Scaled Insights Behavioral AI will identify the personality characteristics of patients with Chronic Kidney Disease who are likely to opt for both peritoneal dialysis and hemodialysis (Phase 1) 2. Scaled Insights Behavioral AI will identify the nudges that are most effective in encouraging or supporting patients with Chronic Kidney Disease in choosing peritoneal dialysis over hemodialysis (Phase 2)
Eligibility Criteria
Inclusion Criteria: * Phase 1: US and UK adult patients aged 18+ years, with Chronic Kidney Disease stage 4-5. * Phase 2: US and UK adult patients aged 18+ years, with Chronic Kidney Disease stage 4-5. Exclusion Criteria: * Phase 1: Young people aged \<18 years. People who do not have Chronic Kidney Disease. People who reside outside of the USA and UK. * Phases 2: Young people aged \<18 years. People who do not have Chronic Kidney Disease stage 4-5. People who reside outside of the USA and UK.
Contact & Investigator
Stuart W Flint, PhD
PRINCIPAL INVESTIGATOR
Scaled Insights
Frequently Asked Questions
Who can join the NCT06533254 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Kidney Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06533254 currently recruiting?
Yes, NCT06533254 is actively recruiting participants. Contact the research team at sflint@scaledinsights.com for enrollment information.
Where is the NCT06533254 trial being conducted?
This trial is being conducted at Dallas, United States.
Who is sponsoring the NCT06533254 clinical trial?
NCT06533254 is sponsored by Scaled Insights. The principal investigator is Stuart W Flint, PhD at Scaled Insights. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.